Match Document Document Title
7090834 Vascular endothelial cell growth factor variants and uses thereof  
The present invention provides VEGF variants having one or more amino acid mutations in the KDR and/or FLT-1 receptor binding domains in the native VEGF sequence and selective binding affinity for...
7074761 Peptides and production and use thereof  
The peptides and precursors thereof, inclusive salts thereof, of the present invention are useful as a pharmaceutical composition, for example as therapeutic or prophylactic agents for...
7071165 LHRH antagonist peptides  
Novel LHRH antagonist peptides, pharmaceutical compositions thereof, and methods of use thereof, are disclosed. The LHRH antagonist comprise a peptide compound, wherein a residue of the peptide...
7041787 Design and use of advanced zinc chelating peptides to regulate matrix metalloproteinases  
The present invention relates to MMP regulators that comprise new synthetic peptides, that comprise amino acid sequences structurally similar to those of MMP binding region of TIMPs, coupled to...
7041635 Factor VIII polypeptide  
The application discloses Factor VIII polypeptides comprising internal deletions of amino acids within the area of residues 741 to 1689, wherein the thrombin cleavage sites at about 741 and about...
7037707 Method for generating influenza viruses and vaccines  
The present invention is based on the discovery that a high titer reassortant influenza virus is produced in mammalian cell culture by replacing the NS gene of the A/PuertoRico/3/24 master strain...
7022669 Echinocandin derivatives, method for preparing same and application as antifungal agents  
A subject of the invention, in all possible isomer forms as well as their mixtures, is the compounds of formula (I): in which either R1: H or CH3 andR2: cyclohexyl substituted by an amine, a...
7012130 Methods of purifying recombinant human erythropoietin from cell culture supernatants  
The present invention relates, in general, to a method of purifying recombinant human erythropoietin (EPO). The present invention also relates to a substantially pure EPO. The method comprises a...
7005290 Best's macular dystrophy gene  
Novel human and mouse DNA sequences that encode the gene CG1CE, which, when mutated, is responsible for Best's macular dystrophy, are provided. Provided are genomic CG1CE DNA as well as cDNA that...
7001982 Non-natural C-linked carbo-β-peptides with robust secondary structures  
Nonnatural C-linked carbo-β-peptides with robust secondary structures, which involves the synthesis of a new class of β-peptides called C-linked carbo-β-peptides. The compounds are favorably...
7001993 Human antithrombin variants  
Human antithrombin variants showing a high protease inhibitory activity even in the absence of heparin wherein at least one of the amino acids at positions 78, 278, 378 and 380 in the amino acid...
7001729 Production of adenine nucleotide translocator (ANT), novel ANT ligands and screening assays therefor  
Compositions and methods are provided for producing adenine nucleotide translocator (ANT) polypeptides and fusion proteins, including the production and use of recombinant expression constructs...
6982247 Compounds exhibiting an antibiotic activity  
The present invention relates to compounds having antibiotic activity which are obtained from body fluids of mollusks, namely of certain West-African snails, to therapeutic drugs comprising these...
6966992 Method of purification of molecules using unbranched terminal alkyldiols  
The current invention provides methods for molecule purification by RP-LC and RP-HPLC that uses unbranched terminal alkyldiols as eluting solvents. In particular, the present invention purifies...
6962978 Polymer conjugates of interferon beta-1a and uses  
An interferon beta polypeptide comprising interferon-beta 1a coupled to a polymer containing a polyalkylene glycol moiety wherein the interferon-beta-1a and the polyalkylene glycol moiety are...
6936475 Chimeric GFP-aequorin as bioluminescent Ca++reporters at the single cell level  
A modified bioluminescent system comprising a fluorescent molecule covalently linked with a photoprotein, wherein said link between the two proteins has the function to stabilize the modified...
6930097 Matrix metalloproteinase and tumor necrosis factor inhibitors  
A compound of formula 1-[3,4-dihydroxy-5-(2-hydroxyethyl)tetrahydrofuran-2-yl]pryi midine-2,4(1H,3H)-dione has inhibitory effects of matrix metalloproteinase-2 (gelatinase A) enzyme and binding of...
6930086 Diglycosylated erythropoietin  
This invention is directed to an erythropoietin mutein having in vivo biological activity for causing bone marrow cells to increase production of reticulocytes and red blood cells, in that the...
6919080 Polypeptide for Haemophilus paragallinarum and process for preparing the same  
A novel peptide obtained from Haemophilus paragallinarum has been found useful for preventing avian infectious coryza. This polypeptide induces production of hemagglutination-inhibition antibody...
6908619 Camp factor of streptococcus uberis  
The CAMP factor gene of Streptococcus uberis (S. uberis) is described, as well as the recombinant production of CAMP factor therefrom. CAMP factors can be used in vaccine compositions for the...
6902720 Cyclic peptide structures for molecular scale electronic and photonic devices  
The present invention discloses a family of cyclic peptide monomers and supramolecular cyclic peptide structures comprising chromophore residues which possess electronic and electro-optic...
6893843 Nucleic acids  
Polypeptides, in particular the polypeptide of formula I: Ala-Gln-Glu-Pro-Val-Lys-Gly-Pro-Val-Ser-Thr-Lys-Pro-Gly-Ser- Cys-Pro-Ile-Ile-Leu-Ile-Arg-Cys-Ala-Met-Leu-Asn-Pro-Pro-Asn- Arg-Cys-Leu-Lys-A...
6890531 Neuronal growth factor galectin-1  
This invention relates to a remedy for neuropathy, such as nerve injury, nerve degeneration, and hypofunction upon nerve grafting, which contains as the active ingredient galectin-1 having an...
6887845 Polypeptoid pulmonary surfactants  
The present invention provides spreading agents based on sequence-specific oligomers comprising a peptoid, a peptide-peptoid chimera, a retropeptoid or a retro(peptoid-peptide) chimera, and...
6884423 Antimicrobial histone H1 compositions, kits, and methods of use thereof  
The invention includes antibiotic pharmaceutical compositions comprising eukaryotic histone H1 protein and methods of using eukaryotic histone H1 protein to kill or to inhibit the growth of...
6878813 Human antithrombin IIIs and methods related thereto  
The present invention discloses modified antithrombin III compounds and methods. The amino acid compounds of the present invention are useful in treating blood clotting disorders, as well as other...
6872803 Peptides  
The present invention provides peptides represented by the following formula (A): wherein Q represents a physiologically active peptide moiety; X each represents the same or different α-amino acid...
6867191 Preparation and use of oligopeptide lyophilisate for gonad protection  
A lyophilizate, method of preparation, and use of the lyophilizate for gonad protection is described. The lyophilizate comprises cetrorelix dissolved in 30% (v/v) acetic acid, transferred to...
6849597 Neuroprotective drug  
An agent for prevention or treatment of diseases involving degeneration or death of nerve cells, characterized by containing a growth hormone secretion promoting substance as an active ingredient,...
6846803 Antagonists specific for the corticotropin-releasing factor receptor type 2 (CRFR2)  
The present invention relates to an antagonist of the ligand of the Corticotropin-Releasing Factor Receptor, type 2 (CRFR2) lacking the 8 to 10 N-terminal amino acids of native sauvagine. The...
6846667 Virulence genes and proteins, and their use  
The present invention is based on the identification of a series of virulence genes in E. coli K1, the products of which may be implicated in the pathogenicity of the organisms. The identification...
6841657 Inhibitors of HIV membrane fusion  
Inhibitors of HIV membrane fusion and a method of identifying drugs or agents which inhibit binding of the N-helix coiled-coil and the C helix of HIV gp41 envelope protein.
6824659 Designed protein pores as components for biosensors  
A mutant staphylococcal alpha hemolysin polypeptide containing a heterologous analyte-binding amino acid which assembles into an analyte-responsive heptameric pore assembly in the presence of a...
6808706 Method for keeping the quality of aqueous parenteral solution of thrombomodulin in storage and distribution  
A method for keeping the quality of an aqueous parenteral solution of thrombomodulin which is not in a frozen or freeze-dried state but in a liquid form in storage and distribution, characterized...
6809177 Process for the conversion of echinocandin class of peptides to their c4-homotyrosine monodeoxy analogues  
The invention relates to a process for the conversion of echinocandin class of peptides to their C4-homotyrosine monodeoxy analogues, particularly mulundocandin to deoxymulundocandin, which...
6800280 Methods for treating HIV-infected patients by the administration of GM-CSF and a protease inhibitor  
Provided are methods for inducing an increase in the number of CD4+ T-lymphocytes in HIV-infected patients by administering human GM-CSF. The GM-CSF may be administered concurrently with at least...
6800492 Chimeric GFP-aequorin as bioluminescent Ca&plus &plus reporters at the single cell level  
A modified bioluminescent system comprising a fluorescent molecule covalently linked with a photoprotein, wherein said link between the two proteins has the function to stabilize the modified...
6787336 DNA encoding growth hormone antagonists  
The present invention relates to DNA molecules which encode antagonists of vertebrate growth hormones obtained by mutation of at least the amino acid corresponding to Glu-119 in bovine growth...
6784154 Method of use of erythropoietin to treat ischemic acute renal failure  
Recombinant erythropoietin is used in a method to prevent ischemic acute renal failure in patients at risk for developing ischemic acute renal failure and to treat fully-developed ischemic acute...
6783764 Actinobacillus pleuropneumoniae subunit vaccine  
The present invention relates to live attenuated bacteria of the genus Actinobacillus pleuropneumoniae that have a mutation in an apxIV gene such that no functional ApxIV toxin can be produced....
6776984 Induced regeneration and repair of damaged neurons and nerve axon myelin  
A method of treatment of and composition for human degenerative neurologic diseases discloses the administration of therapeutically amounts of an enhancement agent, such as thrombopoietin, to...
6767722 Analogs of human basic fibroblast growth factor mutated at one or more of the positions glutamate 89, Aspartate 101 or Leucine 137  
The present invention relates to muteins of human basic fibroblast growth factor with superagonist properties. Both protein and the respective encoding nucleic acid species are disclosed. The...
6762280 High throughput assays for the proteotytic activities of clostridial neurotoxins  
In this application is described substrates for high-throughput assays of clostridial neurotoxin proteolytic activities. Two types of substrates are described for use in assays for the proteolytic...
6759216 Glycosylated, low antigenicity low immunogenicity factor VIII  
The development of inhibitory antibodies to blood coagulation factor VIII (fVIII) results in a severe bleeding tendency. These antibodies arise in patients with hemophilia A (hereditary fVIII...
6756357 Variants of human ciliary neurotrophic factor (hCNTF)  
The variants of human ciliary neutrophic factor (hCNTF) according to the present invention are characterized by substitution of phenylalanine 152 and/or lysine 155 with alanine. These variants...
6750321 Insulin-like growth factor agonist molecules  
Peptides are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist peptides are useful to increase serum and...
6747125 Peptide intermediates for making GnRH antagonists  
Peptides which include unnatural amino acids and which either promote or inhibit the secretion of gonadotropins by the pituitary gland and inhibit the release of steroids by the gonads....
6743778 Apo-AI/AII peptide derivatives  
The present invention concerns therapeutic agents that mimic the activity of Apo-AI amphipathic helix peptide. In accordance with the present invention, the compounds of the invention comprise: a....
6733997 Isolated nucleic acids encoding a secretory signal for expression and secretion of heterologous recombinant proteins  
A universal secretory signal originally derived from a piscine vitellogenin (Vtg) gene is inserted into various expression vectors for driving the secretion of the recombinant protein into the...
6730486 Human βTrCP protein  
The present invention relates to the human βTrCP protein for the targeting of proteins towards proteasome degradation pathways, which is capable of interacting with the Vpu protein of HIV-1 virus,...